InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.74
(
-0.02%
)
US TECH 100
17,716.40
(
0.19%
)
Dow Jones
39,454.62
(
-0.15%
)
Brent Oil
83.30
(
1.10%
)
Bitcoin
63,083.58
(
2.66%
)
Post# of 672
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

realfast95

Send PM Follow Ignore
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

realfast95

Re: realfast95 post# 73

Friday, 10/07/2016 1:27:28 PM

Friday, October 07, 2016 1:27:28 PM

Post# of 672
Perhaps it was this text in the SA article that got the reaction.
I knew Cantor had a $21 target but not the reason.

Cantor Fitzgerald analyst reiterated a Buy rating on Egalet on August 4th and again on September 8th with a price target of $21. "We believe that Arymo is a superior product to Pfizer's Embeda, which does some 9,000 scripts per month."
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up